UVM Reference Number: C649
Summary:
Opioid addiction treatment through a portable device, combined with automated check-ins, in-person testing, and HIV/HepB education
Background:
Opioid addiction in American has hit epidemic levels and despite the demonstrated need for and the effectiveness of current treatments, waitlists persist. While waiting for treatments, patients are at high risk for illicit drug use, engaging in criminal activity, contracting infectious disease, and death.
Technology Overview:
Interim buprenorphine treatment (IBT) offers a comprehensive solution with daily doses administered through a computerized, portable device, combined with automated check-ins, in-person testing, and HIV/HepB education. Compared to patients who received no treatment while waiting, patients who receive IBT have decreased illicit opioid use, reduced withdrawal symptoms and cravings, increased HIV/HepB education, and significantly lower levels of depression. These results translate into an effective way to bridge waitlists for at-risk populations and reduce harm to patients and society.
Further Details:
- Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults Peck et alPMID 31991327
- Innovations in efforts to expand treatment for opioid use disorder Sigmon et al PMID 31445112
- Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms Streck et al PMID 29939049
- Interim Buprenorphine vs. Waiting List for Opioid Dependence Sigmon et al PMID 28002704
Benefits:
- Reduces harm to patients and society.
- Reduces barrier of in-person clinic visits.
- Self-directed, providing patients control over their treatment.
- Low abuse and overdose liability.
Applications:
- Interim treatment to bridge waitlists and engage patients with the treatment system.
Opportunity:
Protocols and know-how available for licensing and research collaboration.
Seeking:
- Licensing
- Development partner
